A.V. ZAKHAROV, I.E. POVERENNOVA, E.V. KHIVINTSEVA

Samara State Medical University, 159 Tashkentskaya Str., Samara, Russian Federation, 443095

 Zakharov A.V. ― PhD (medicine), Associate Professor of the Department of Neurology and Neurosurgery, tel. (846) 956-16-84, e-mail: [email protected],  ORCID ID: 0000-0003-1709-6195

Poverennova I.E. ― D. Sc. (medicine), Professor of the Department of Neurology and Neurosurgery, tel. (846) 956-16-84, e-mail: [email protected],  ORCID ID: 0000-0002-2594-461X

Khivintseva E.V. ― PhD (medicine), Associate Professor of the Department of Neurology and Neurosurgery, tel. (846) 956-16-84, e-mail: [email protected],  ORCID ID: 0000-0002-1878-7951

 Objective ― to assess changes in multimodal evoked potentials in patients with clinically isolated syndrome (CIS). To evaluate their contribution to the expansion of the “dissemination in space” definition, which is necessary for the clinically reliable diagnosis of multiple sclerosis.

Material and methods. The study was conducted on acoustic stem, visual and somatosensory evoked potentials of 30 patients with monofocal CIS and 13 patients with multifocal CIS. The studied groups were comparable in severity of neurological deficit and age.

Results. According to the visual evoked potentials, no differences between the studied groups were found. There is an increase in the latency of acoustic inter-peak interval I-V to 3.8 ms (p=0.03), as well as the latency of N11 peak of somatosensory evoked potential up to 10.3 ms (p=0.04) in patients with multifocal CIS. The changes in somatosensory evoked potentials reflect subclinical lesion of the cervical spinal cord.

Conclusion. The use of multimodal evoked potentials allows identifying subclinical demyelination foci, which may serve as confirmation of the «dissemination in space» indicator in multiple sclerosis.

Key words: clinically isolated syndrome, evoked potentials, diagnosis.

(For citation: Zakharov A.V., Poverennova I.E., Khivintseva E.V. Multimodal evoked potentials in clinically isolated syndrome. Practical Medicine. 2018)

REFERENCES

1. Miller D.H., Chard D.T., Ciccarelli O. Clinically isolated syndromes. Lancet Neurol., 2012, no. 1, pp. 157–169
2. Miller D.H., Weinshenker B.G., Filippi M., et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple Sclerosis, 2008; no. 14, pp. 1157–1174.
3. Zakharov A.V., Khivintseva E.V., Poverennova I.E., Gindullina E.A., Vlasov Ya.V., Sineok E.V. Evaluation of risks of transformation of a monofocal clinically isolated syndrome in clinically significant multiple sclerosis. Journal of Neurology and Psychiatry named after S.S. Korsakov, 2013; 113 (2-2), pp.  28-31. (in Rus.).
4. Zakharov A.V., Poverennova I.E., Khivintseva E.V., Greshnova I.V., Gendullina E.A. Analysis of the probability of transition of a monofocal clinically isolated syndrome to clinically reliable multiple sclerosis. Saratov Journal of Medical Scientific Research, 2012, no. 8 (2), pp. 432-435. (in Rus.).
5. Poverennova I.E., Romanova T.V., Zakharov A.V., Khivintseva E.V. Early detection of cognitive impairment in patients with multiple sclerosis. Saratov Journal of Medical Scientific Research, 2017; no. 13(1), pp. 164-168. (in Rus.).
6. Zakharov A.V., Afrosina E.Yu., Khivintseva E.V., Antipov O.I. Quality of night sleep in patients with multiple sclerosis. Journal of Neurology and Psychiatry after S.S. Korsakov, 2016; no. 116 (2-2), pp. 41-43. (in Rus.).
7. Zakharov A.V., Vlasov Ya.V., Poverennova I.E., Khivintseva E.V., Antipov O.I. Features of postural disorders in patients with multiple sclerosis. Journal of Neurology and Psychiatry after S.S. Korsakov, 2014, no. 114(2-2), pp. 55-58. (in Rus.).
8. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 1983; no. 33, pp. 1444–1452.
9. Leray E., Yaouanq J., Le Page E., Coustans M., Laplaud D., Oger J., Edan G. Evidence for a two-stage disability progression in multiple sclerosis. Brain, 2010, no. 133, pp. 1900–1913.
10. Runmarker B., Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain, 1993; no. 116, pp. 117–134.
11. Confavreux C., Vukusic S., Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain, 2003; no. 126, pp. 770–782.
12. Dobson R., Ramagopalan S., Davis A., Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry, 2013; no. 84, pp. 909–914.
13. Tintore M., Rovira A., Rio J., Nos C., Grive E., Tellez N., et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology, 2006, no. 67, pp. 968–972.
14. Fisniku L.K., Brex P.A., Altmann D.R., Miszkiel K.A., Benton C.E., Lanyon R., et al. Disability and T2 MRI lesions: a 20-year followup of patients with relapse onset of multiple sclerosis. Brain, 2008, no. 131, 808–817.
15. Young J., Quinn S., Hurrell M., Taylor B. Clinically isolated acute transverse myelitis: prognostic features and incidence. Multiple Sclerosis, 2009, no. 15, pp. 1295–302.
16. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O’connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Multiple Diagnostic Criteria for MS: 2010 Revisions to the Mcdonald Criteria. Ann Neurol, 2011, 69(2), pp. 292-302.
17. Leocani L., Rovaris M., Boneschi F.M., Medaglini S., Rossi P., Martinelli V., et al. Multimodal evoked potentials to assess the evolution of multiple MS: a longitudinal study. J Neurol Neurosurg Psychiatry, 2006, 77, pp. 1030-1035.
18. Zivadinov R., Leist T.P. Clinical-Magnetic Resonance Imaging Correlations in Multiple Sclerosis. J Neuroimaging, 2005; 15(4), pp. 10–21.
19. Leocani L., Comi G.. Neurophysiological Markers. Neurology Science, 2008, 29(2), pp. 218–21.
20. Feuillet L., Pelletier J., Suchet L., Rico A., Kraemer A., Pouget J., Attarian S. Prospective Clinical and Electrophysiological Follow-up on a Multiple MS Population Treated with Interferon Beta-1A: A Pilot Study. Multiple Sclerosis, 2007, 13(3), pp. 348-356.